ASX:ANP Antisense Therapeutics (ANP) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free ANP Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.32 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield4.58%Price TargetN/A Stock AnalysisStock Analysis Get Antisense Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Antisense Therapeutics Stock (ASX:ANP)Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. ANP Stock News HeadlinesApril 15, 2024 | finance.yahoo.comAnpario plc's (LON:ANP) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?April 5, 2024 | msn.comScoPo’s (actually Wilkie’s) Powerplays: Blinklab soars 32.5% in first healthcare IPO of 2024April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 1, 2024 | msn.comANP improves net income to MAD 105 mln in 2023April 1, 2024 | msn.comANP slams Qaiser's advice to snap ties with govtMarch 31, 2024 | ca.news.yahoo.comDutch nightclub hostage drama ends peacefully with arrest of suspectMarch 31, 2024 | msn.comDutch nightclub hostage drama ends peacefullyMarch 20, 2024 | reuters.comDutch court finds KLM ads were misleading in 'greenwashing' suit -ANPApril 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 6, 2024 | msn.comANP calls for judicial commission to probe rigging in Feb 8 pollsMarch 1, 2024 | msn.comJUI-F, ANP shun elections of top officesFebruary 29, 2024 | msn.comWon't participate in election to posts of president, PM, speaker: ANP chiefFebruary 13, 2024 | msn.comANP's Aimal Wali rejects polls resultsJanuary 22, 2024 | finance.yahoo.comWe Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth CarefullyJanuary 15, 2024 | msn.comECP allocates 'lantern' symbol to ANPJanuary 13, 2024 | msn.comANP withdraws from NA-242 in favour of Shehbaz SharifJanuary 13, 2024 | msn.comElection 2024 ECP allots election symbols to ANPDecember 18, 2023 | finance.yahoo.comSome Confidence Is Lacking In Anpario plc's (LON:ANP) P/ENovember 25, 2023 | msn.comMQM-P, ANP join forces for pollsSeptember 27, 2023 | reuters.comDutch court rules Chemours liable for environmental damage caused by PFAS - ANPJuly 22, 2023 | msn.comDozens of ANP leaders in KP join Peoples PartyJuly 7, 2023 | yahoo.comDutch government to resign over asylum policy -ANPJuly 7, 2023 | msn.comDutch government to resign over asylum policy, ANP reportsJune 29, 2023 | reuters.comNetherlands talking to three suppliers to build new nuclear power plants - ANPJune 17, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn SituationMay 17, 2023 | morningstar.comKymera Therapeutics Inc Ordinary SharesMay 10, 2023 | marketwatch.comAntisense & RNAi Therapeutics Market 2023-2030 Study for Research by Industry Key Factors and Key PlayersSee More Headlines Receive ANP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antisense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolASX:ANP CUSIPN/A CIKN/A Webwww.antisense.com.au Phone61 3 9827 8999FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-41.69% Debt Debt-to-Equity Ratio1.42 Current Ratio4.51 Quick Ratio18.16 Sales & Book Value Annual Sales$1.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.18 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares901,550,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.06 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. James Garner B.Sc (Hons) (Age 50)B.Sc., M.A., M.A.I.C.D., M.B.A., MBA, CEO, MD & Director Comp: $9.77kMr. Phillip Allen Hains BBus(Acc) (Age 64)C.A., M.B.A., CFO & Joint Company Secretary Comp: $160.28kDr. Anthony FilippisChief Operating OfficerMs. Alicia MellorsJoint Company SecretaryKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All CompetitorsInsidersJames GarnerSold 6,690,000 sharesTotal: $401,400.00 ($0.06/share)James GarnerBought 100,000 shares on 11/17/2023Total: $6,100.00 ($0.06/share)Ben PriceBought 400,000 shares on 9/26/2023Total: $28,400.00 ($0.07/share)Charmaine GittlesonSold 600,000 sharesTotal: $30,000.00 ($0.05/share)James GarnerBought 300,000 shares on 5/8/2023Total: $22,200.00 ($0.07/share) ANP Stock Analysis - Frequently Asked Questions How were Antisense Therapeutics' earnings last quarter? Antisense Therapeutics Limited (ASX:ANP) posted its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. What other stocks do shareholders of Antisense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN). This page (ASX:ANP) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antisense Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
